UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K/A

 

Amendment No.1

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): October 12, 2023

 

BIONEXUS GENE LAB CORP.

(Exact name of Company as specified in charter)

 

Wyoming

333-229399

35-2604830

(State or another jurisdiction

of incorporation)

(Commission

File No.)

(IRS Employer

Identification No.)

 

Unit 2, Level 10, Tower B, Avenue 3

The Vertical Business Suite II Bangar South

No. 8 Jalan Kerinchi

Kuala Lumpur, Malaysia, 59200

(Address of Principal Executive Offices) (Zip code)

 

+60 1221-26512

(Company’s Telephone number, including area code)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions (see General Instruction A.2. below):

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company   ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☐

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

Common Stock, no par value

 

BGLC

 

Nasdaq Capital Market

 

 

 

 

Explanatory Note

 

This Current Report on Form 8-K/A (this “Current Report”) amends the Current Report on Form 8-K filed by BioNexus Gene Lab Corp. (the “Company”) with the Securities and Exchange Commission on October 16, 2023 (the “Original Report”). It is being filed to update the Company’s disclosure under Item 5.02 of the Original Report to disclose the family relationship between the newly appointed Chief Executive Officer and director and the Company’s Chief Financial Officer (“CFO”). The Original Report otherwise remains unchanged.

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

Mr. Leong has a family relationship with the Company’s CFO, Wei Li Leong. Ms. Wei Li Leong is the daughter of Mr. Leong. 

 

 

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

BIONEXUS GENE LAB CORP

 

 

 

 

Date: October 30, 2023

By:

/s/ Chi Yuen Leong

 

 

Name:

Chi Yuen Leong

 

 

Title:

Chief Executive Officer

 

 

 

3

 

v3.23.3
Cover
Oct. 12, 2023
Cover [Abstract]  
Entity Registrant Name BIONEXUS GENE LAB CORP.
Entity Central Index Key 0001737523
Document Type 8-K/A
Amendment Flag true
Amendment Description This Current Report on Form 8-K/A (this “Current Report”) amends the Current Report on Form 8-K filed by BioNexus Gene Lab Corp. (the “Company”) with the Securities and Exchange Commission on October 16, 2023 (the “Original Report”). It is being filed to update the Company’s disclosure under Item 5.02 of the Original Report to disclose the family relationship between the newly appointed Chief Executive Officer and director and the Company’s Chief Financial Officer (“CFO”). The Original Report otherwise remains unchanged.
Entity Emerging Growth Company true
Document Period End Date Oct. 12, 2023
Entity Ex Transition Period false
Entity File Number 333-229399
Entity Incorporation State Country Code WY
Entity Tax Identification Number 35-2604830
Entity Address Address Line 1 Unit 2, Level 10, Tower B, Avenue 3
Entity Address Address Line 2 The Vertical Business Suite II Bangar South
Entity Address Address Line 3 No. 8 Jalan Kerinchi
Entity Address City Or Town Kuala Lumpur
Entity Address Postal Zip Code 59200
City Area Code 60
Local Phone Number 1221-26512
Security 12b Title Common Stock, no par value
Trading Symbol BGLC
Security Exchange Name NASDAQ
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Entity Address Country MY
BioNexus Gene Lab (PK) (USOTC:BGLC)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024 Click aqui para mais gráficos BioNexus Gene Lab (PK).
BioNexus Gene Lab (PK) (USOTC:BGLC)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024 Click aqui para mais gráficos BioNexus Gene Lab (PK).